PL2535716T3 - Tumor marker and therapeutic target - Google Patents

Tumor marker and therapeutic target

Info

Publication number
PL2535716T3
PL2535716T3 PL12183760T PL12183760T PL2535716T3 PL 2535716 T3 PL2535716 T3 PL 2535716T3 PL 12183760 T PL12183760 T PL 12183760T PL 12183760 T PL12183760 T PL 12183760T PL 2535716 T3 PL2535716 T3 PL 2535716T3
Authority
PL
Poland
Prior art keywords
therapeutic target
tumor marker
tumor
marker
therapeutic
Prior art date
Application number
PL12183760T
Other languages
Polish (pl)
Inventor
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Frances Balkwill
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2535716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of PL2535716T3 publication Critical patent/PL2535716T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
PL12183760T 2007-09-18 2008-09-18 Tumor marker and therapeutic target PL2535716T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target

Publications (1)

Publication Number Publication Date
PL2535716T3 true PL2535716T3 (en) 2017-06-30

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08806315T PL2176664T3 (en) 2007-09-18 2008-09-18 CCR4 AS A Cancer Marker
PL12182790.1T PL2533047T3 (en) 2007-09-18 2008-09-18 CCR4 AS A THERAPEUTIC PURPOSE FOR CANCER
PL12183760T PL2535716T3 (en) 2007-09-18 2008-09-18 Tumor marker and therapeutic target

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL08806315T PL2176664T3 (en) 2007-09-18 2008-09-18 CCR4 AS A Cancer Marker
PL12182790.1T PL2533047T3 (en) 2007-09-18 2008-09-18 CCR4 AS A THERAPEUTIC PURPOSE FOR CANCER

Country Status (11)

Country Link
US (2) US9134293B2 (en)
EP (3) EP2176664B1 (en)
JP (2) JP5774309B2 (en)
AU (1) AU2008300413B2 (en)
CA (1) CA2699702C (en)
DK (3) DK2535716T3 (en)
ES (3) ES2588507T3 (en)
GB (1) GB0718167D0 (en)
PL (3) PL2176664T3 (en)
RU (2) RU2529797C2 (en)
WO (1) WO2009037454A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (en) 1988-10-06 1994-06-22 株式会社大金製作所 Air rotary joint sealing device
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
HK1212389A1 (en) * 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
MX356163B (en) 2011-12-01 2018-05-16 Chemocentryx Inc Substituted anilines as ccr(4) antagonists.
GB2512857A (en) 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
ES2884255T3 (en) 2013-11-06 2021-12-10 Janssen Biotech Inc Anti-CCL17 antibodies
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CA2962812A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
CN107624071A (en) * 2015-04-17 2018-01-23 诺福泰克公司 Lung Cancer Treatments
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
JP7177445B2 (en) * 2017-05-19 2022-11-24 真吾 前田 Inhibition of regulatory T cell infiltration by CCR4 inhibition and therapeutic method for canine neoplastic disease
CN112601526B (en) 2018-08-29 2025-10-03 凯莫森特里克斯股份有限公司 Combination therapy with a C-C chemokine receptor 4 (CCR4) antagonist and one or more checkpoint inhibitors
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
CN100455599C (en) 2000-03-03 2009-01-28 协和发酵工业株式会社 Gene recombinant antibody and its antibody fragment
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
EP1326617B9 (en) 2000-10-18 2006-10-25 Schering Aktiengesellschaft Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
CA2439279A1 (en) 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
NZ531069A (en) 2001-08-10 2007-01-26 Topigen Pharma Inc Methods for modulating viral infection of cells by modulating a binding interaction between a CCR1, CCR2, CCR3, CCR4, CCR5 and/or CCR8 receptor and a surface protein of the virus
PT1449850E (en) 2001-08-31 2011-02-02 Kyowa Hakko Kirin Co Ltd ANCHORED HUMAN ANTIBODIES IN DRUGS AND FRAGMENTS OF THESE ANTIBODIES
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
EP1592708A2 (en) * 2003-02-14 2005-11-09 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (en) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (en) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co Chemokine receptor antagonist and medical use thereof
AU2004279739A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Composition of antibody capable of specifically binding CCR4
ATE486611T1 (en) 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd MEDICINAL CONTAINING A GENETICALLY MODIFIED ANTIBODY AGAINST CHEMOKINE RECEPTOR-CCR4
WO2005082865A1 (en) 2004-02-27 2005-09-09 Astellas Pharma Inc. Fused bicyclic pyrimidine derivative
JP2007217282A (en) 2004-03-04 2007-08-30 Astellas Pharma Inc Substituted pyrimidine derivatives
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (en) 2004-06-21 2007-10-18 Astellas Pharma Inc Quinazoline derivatives
RU2296328C1 (en) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Method for detecting the predisposition to oncological diseases and diagnostic kit for its implementation
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8193159B2 (en) 2006-02-14 2012-06-05 Noxxon Pharma Ag MCP-1 binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
JP2010539508A (en) 2010-12-16
DK2176664T3 (en) 2014-01-20
US10261099B2 (en) 2019-04-16
EP2533047B1 (en) 2016-05-11
DK2533047T3 (en) 2016-08-22
EP2176664B1 (en) 2013-11-06
EP2176664A2 (en) 2010-04-21
CA2699702A1 (en) 2009-03-26
AU2008300413A1 (en) 2009-03-26
US20160223572A1 (en) 2016-08-04
RU2529797C2 (en) 2014-09-27
WO2009037454A3 (en) 2009-05-07
JP2015212703A (en) 2015-11-26
US9134293B2 (en) 2015-09-15
CA2699702C (en) 2018-03-06
PL2176664T3 (en) 2014-04-30
AU2008300413B2 (en) 2014-09-11
EP2535716B1 (en) 2016-11-02
RU2014128513A (en) 2016-02-10
ES2443541T3 (en) 2014-02-19
ES2588507T3 (en) 2016-11-03
EP2535716A3 (en) 2013-03-13
ES2612690T3 (en) 2017-05-18
RU2010123921A (en) 2011-12-20
GB0718167D0 (en) 2007-10-31
WO2009037454A2 (en) 2009-03-26
PL2533047T3 (en) 2016-11-30
EP2533047A1 (en) 2012-12-12
EP2535716A2 (en) 2012-12-19
US20100278844A1 (en) 2010-11-04
DK2535716T3 (en) 2017-02-13
JP5774309B2 (en) 2015-09-09
JP6234967B2 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
PL2535716T3 (en) Tumor marker and therapeutic target
DK2171090T3 (en) Gene expression markers for tumor resistance to HER2 inhibitor therapy
PL2567707T3 (en) Composition of tumor associated peptides and related vaccine against cancer
BR112012004546A2 (en) "dll4-ligand protein therapy"
DK2185164T3 (en) COMPOSITION AND THERAPEUTIC ANTITUMORVACCINE
BRPI0812562A2 (en) anti-cd20 therapeutic compositions and methods
DE502007002254D1 (en) Medical laser target marker and its use
EP2241332A4 (en) THERAPEUTIC AGENT AGAINST PRURIT
DK2144905T3 (en) Therapeutic agents
EP2127671A4 (en) THERAPEUTIC AGENT AGAINST CANCER
HUE039385T2 (en) ABCB5 targeting cancer therapy
EP2115162A4 (en) ADRB2-CANCER MARKER
IL220386B (en) Preparations for the elimination of cancer tumors and their uses
EP2143353A4 (en) OUTSOLE AND SHOES
BRPI0821248A2 (en) Kinesin Inhibitors as Therapeutic Cancer Drugs
BRPI0921947A2 (en) therapeutic protein formulations
HUE036071T2 (en) Therapeutic preparations containing Macitentan
DE602008001981D1 (en) POSITION AND THERAPEUTIC USE
GB0717101D0 (en) Tumour marker
EP2334695A4 (en) THERAPEUTIC RIBONUCLEASES
BRPI0810384A2 (en) ANTICHANE ENZYMATIC THERAPY
EP2277400A4 (en) MAGNETOTHERAPY SHOE
EP2637692A4 (en) ANTIBODIES AGAINST THE MARKER 8 TUMOR ENDOTHELIAL
BRPI0820410A2 (en) Therapeutic Substituted Lactans
HUE038563T2 (en) Cancer treatment procedure